Abstract
The pivotal role of haemoglobin as one of the targets in the holistic management of dialysis patients was the focus of the first published anaemia guidelines by KDOQI in 1997. Since the introduction of erythropoietin to anaemia management in chronic kidney disease, there has been a continuous debate on the optimal haemoglobin target required to achieve the desirable clinical outcome whether in survival or quality of life. With the unequivocal evidence of the impact of these agents on relatively better quality of life and reduced need for red-cell transfusion with the anticipated potential complications attached to it, there is an element of uncertainty about the exact risk of these agents on chronic kidney disease patients. Iron deficiency is the other area that attracts a lot of interest in anaemia management in chronic kidney disease. Absolute and relative iron deficiencies are recognised for a long time as important contributing factors for anaemia development in different stages of chronic kidney disease. More importantly, response to erythropoiesis stimulating agents (ESAs) is suboptimal in the presence of iron deficiency. Most of the up-to-date anaemia guidelines emphasise on the central role of iron in anaemia management. Disappointing enough, iron treatment recommendations are either not graded or scored low. This emphasises the unmet need for better quality evidence to address a confusing dilemma in iron treatment in this group of patients. Disproportionately, a large number of high-quality and well-designed studies became available in ESA treatment area which allowed for high-rank quality of evidence. Questions that remain without clear answers are: When to start iron treatment? Which route of administration to use? What are the targets of iron treatment? What are the best biochemical variables that reflect iron status? A very limited number of reasonable quality studies have tried to answer some of these questions. I included some of those trials that attracted a lot of debate in this area and have remarkable impact on anaemia management in chronic kidney disease patients whether on dialysis or not. I also randomly included some of the landmark ESA trials at different levels of chronic kidney disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070–6.
Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997;29:319–33.
Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide) line(s). Kidney Int. 2012;82(9):952–60.
Agarwal R. Is i.v. iron really superior in CKD patients not on dialysis? Kidney Int. 2006;70(6):1188.
Valliant A, Hofmann RM. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. Int J Nanomedicine. 2013;8:3297–307.
KDOQI; National Kidney Foundation. II. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 Suppl 3):S16–85.
Levin A. Understanding recent hemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007;22(2):309–12.
Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schünemann HJ, Jaeschke R, Guyatt GH. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594–6.
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012;suppl 2(4):279–335.
Roger SD. Chronic kidney disease, anemia, and epoetin. N Engl J Med. 2007;356(9):958; author reply 958–9.
Mikhail A, Goldsmith D. Chronic kidney disease, anemia, and epoetin. N Engl J Med. 2007;356(9):956–7.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Anemia of CKD—the CHOIR study revisited. Nephrol Dial Transplant. 2007;22(7):1806–10.
Goldsmith D, Covic A. Time to Reconsider Evidence for Anemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant. 2010;25(6):1734–7.
Wright RJ, Kanagasundaram NS, Quinton R. Darbepoetin alfa and chronic kidney disease. N Engl J Med. 2010;362(7):653; author reply 655.
Minnerup J, Schäbitz WR. Darbepoetin alfa and chronic kidney disease. N Engl J Med. 2010;362(7):653–4; author reply 655.
Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJ, Singh AK, Solomon SD, Uno H, Pfeffer MA, TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011;124(25):2903–8.
Locatelli F, Del Vecchio L, Casartelli D. Darbepoetin alfa and chronic kidney disease. N Engl J Med. 2010;362(7):654–5; author reply 655.
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA. Trial to reduce cardiovascular events with aranesp therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55.
Besarab A, Goodkin DA, Nissenson AR, Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study – follow-up. N Engl J Med. 2008;358(4):433–4.
Sklar AH, Narsipur S. Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin. N Engl J Med. 1998;339(27):2023; author reply 2023–4.
Gonzales F. Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin. N Engl J Med. 1998;339(27):2023; author reply 2023–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
El Kossi, M. (2015). Anemia in Chronic Kidney Disease Clinical Trials: A Critical Appraisal. In: El Kossi, M., Khwaja, A., El Nahas, M. (eds) Informing Clinical Practice in Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-319-10292-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-10292-4_6
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10291-7
Online ISBN: 978-3-319-10292-4
eBook Packages: MedicineMedicine (R0)